(NASDAQ: MRNA) Moderna's forecast annual revenue growth rate of 0.23% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 99.6%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.68%.
Moderna's revenue in 2025 is $2,232,000,000.On average, 27 Wall Street analysts forecast MRNA's revenue for 2025 to be $757,136,894,256, with the lowest MRNA revenue forecast at $663,373,811,376, and the highest MRNA revenue forecast at $862,620,362,496. On average, 27 Wall Street analysts forecast MRNA's revenue for 2026 to be $773,545,433,760, with the lowest MRNA revenue forecast at $521,166,469,008, and the highest MRNA revenue forecast at $960,290,240,496.
In 2027, MRNA is forecast to generate $898,562,877,600 in revenue, with the lowest revenue forecast at $430,919,501,736 and the highest revenue forecast at $1,266,973,657,416.